WGU D116
WGU D116 Advanced Pharmacology OA & ACTUAL
EXAM 2026/2027 | Verified Questions and Correct
Detailed Answers | Pass Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1-30)
Q1: Which of the following best describes pharmacokinetics?
• A) The study of drug effects on the body
• B) The study of drug absorption, distribution, metabolism, and excretion (ADME)
• C) The study of drug toxicity
• D) The study of drug interactions
Answer: B
Rationale: Pharmacokinetics is "what the body does to the drug" and encompasses ADME.
Pharmacodynamics is "what the drug does to the body" and describes drug effects .
Q2: The "first-pass effect" refers to:
• A) Rapid intravenous administration
• B) Drug metabolism in the liver before reaching systemic circulation
• C) Drug excretion by the kidneys
• D) Drug binding to plasma proteins
Answer: B
Rationale: The first-pass effect reduces the bioavailability of orally administered drugs because they
are metabolized in the liver before reaching systemic circulation. Drugs like nitroglycerin and
morphine require higher oral doses or alternative routes .
Q3: Bioavailability is defined as:
• A) The speed of drug absorption
• B) The fraction of an administered dose that reaches systemic circulation unchanged
• C) The volume of distribution
• D) The half-life of the drug
Answer: B
, WGU D116
Rationale: Bioavailability measures the extent of drug absorption and first-pass metabolism. IV
administration has 100% bioavailability; oral bioavailability is reduced by first-pass metabolism and
absorption barriers .
Q4: Which route of administration has the highest bioavailability?
• A) Oral
• B) Subcutaneous
• C) Intravenous (IV)
• D) Intramuscular (IM)
Answer: C
Rationale: IV administration bypasses absorption barriers and first-pass metabolism, delivering
100% of the dose to systemic circulation .
Q5: A drug with a high volume of distribution (e.g., digoxin) is characterized by:
• A) High plasma concentration
• B) Low plasma concentration (distributes widely into tissues)
• C) Rapid renal excretion
• D) Minimal tissue binding
Answer: B
Rationale: High Vd indicates extensive tissue binding and means most drug is in tissues, not plasma.
This requires large loading doses to achieve therapeutic plasma levels. Low Vd indicates primarily
plasma binding .
Q6: The half-life (t½) of a drug is:
• A) The time required for 50% of the drug to be eliminated
• B) The time required for the drug to reach peak concentration
• C) The time required for the drug to be completely eliminated
• D) The time required for the drug to reach steady state
Answer: A
Rationale: Half-life determines dosing interval. It takes approximately 4-5 half-lives to reach steady
state and to eliminate the drug .
Q7: Steady state of a drug is typically reached after approximately:
, WGU D116
• A) One half-life
• B) 2-3 half-lives
• C) 4-5 half-lives
• D) 10 half-lives
Answer: C
Rationale: Steady state is reached when the rate of drug administration equals the rate of
elimination, usually after 4-5 half-lives. For a drug with a 24-hour half-life, steady state is reached in
about 5 days .
Q8: The loading dose of a drug is intended to:
• A) Maintain steady state
• B) Achieve therapeutic concentration rapidly
• C) Prolong the half-life
• D) Reduce side effects
Answer: B
Rationale: Loading doses rapidly achieve therapeutic concentrations, especially for drugs with long
half-lives .
Q9: A drug with a narrow therapeutic index requires:
• A) Once-daily dosing regardless of half-life
• B) Careful monitoring of drug levels and clinical response
• C) No monitoring as it is very safe
• D) Administration with food to enhance absorption
Answer: B
Rationale: Narrow therapeutic index drugs have a small margin between effective and toxic doses
(e.g., warfarin, digoxin, lithium, aminoglycosides), requiring therapeutic drug monitoring and close
clinical observation .
Q10: The therapeutic index is best defined as:
• A) The difference between maximum and minimum dose
• B) The ratio of toxic dose (TD50) to effective dose (ED50)
• C) The half-life of a drug
• D) Drug potency
, WGU D116
Answer: B
Rationale: A narrow therapeutic index indicates a small margin of safety and requires therapeutic
drug monitoring .
Q11: Which of the following scenarios best describes a drug acting as a partial agonist?
• A) A drug that binds to a receptor and produces the maximum possible response
• B) A drug that binds to a receptor, produces a submaximal response, and blocks other
agonists from binding
• C) A drug that binds to a receptor and prevents all endogenous and exogenous agonists from
acting
• D) A drug that binds to an allosteric site to enhance the effect of an endogenous agonist
Answer: B
Rationale: Partial agonists bind to the same receptor site as full agonists but produce a submaximal
response even at full receptor occupancy, while simultaneously blocking full agonists from binding .
Q12: A drug that binds to a receptor and produces a maximal biological response is classified as
a(n):
• A) Partial agonist
• B) Competitive antagonist
• C) Full agonist
• D) Inverse agonist
Answer: C
Rationale: Agonists have both high affinity for a receptor and high intrinsic activity, meaning they
fully activate the receptor to elicit a maximal response .
Q13: An antagonist drug:
• A) Activates the receptor
• B) Blocks the receptor (prevents agonist binding)
• C) Has no affinity for the receptor
• D) Is always irreversible
Answer: B
Rationale: An antagonist has high affinity for a receptor but no intrinsic activity. It binds to the
receptor and blocks the action of endogenous ligands or agonists without producing a biological
response .
WGU D116 Advanced Pharmacology OA & ACTUAL
EXAM 2026/2027 | Verified Questions and Correct
Detailed Answers | Pass Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1-30)
Q1: Which of the following best describes pharmacokinetics?
• A) The study of drug effects on the body
• B) The study of drug absorption, distribution, metabolism, and excretion (ADME)
• C) The study of drug toxicity
• D) The study of drug interactions
Answer: B
Rationale: Pharmacokinetics is "what the body does to the drug" and encompasses ADME.
Pharmacodynamics is "what the drug does to the body" and describes drug effects .
Q2: The "first-pass effect" refers to:
• A) Rapid intravenous administration
• B) Drug metabolism in the liver before reaching systemic circulation
• C) Drug excretion by the kidneys
• D) Drug binding to plasma proteins
Answer: B
Rationale: The first-pass effect reduces the bioavailability of orally administered drugs because they
are metabolized in the liver before reaching systemic circulation. Drugs like nitroglycerin and
morphine require higher oral doses or alternative routes .
Q3: Bioavailability is defined as:
• A) The speed of drug absorption
• B) The fraction of an administered dose that reaches systemic circulation unchanged
• C) The volume of distribution
• D) The half-life of the drug
Answer: B
, WGU D116
Rationale: Bioavailability measures the extent of drug absorption and first-pass metabolism. IV
administration has 100% bioavailability; oral bioavailability is reduced by first-pass metabolism and
absorption barriers .
Q4: Which route of administration has the highest bioavailability?
• A) Oral
• B) Subcutaneous
• C) Intravenous (IV)
• D) Intramuscular (IM)
Answer: C
Rationale: IV administration bypasses absorption barriers and first-pass metabolism, delivering
100% of the dose to systemic circulation .
Q5: A drug with a high volume of distribution (e.g., digoxin) is characterized by:
• A) High plasma concentration
• B) Low plasma concentration (distributes widely into tissues)
• C) Rapid renal excretion
• D) Minimal tissue binding
Answer: B
Rationale: High Vd indicates extensive tissue binding and means most drug is in tissues, not plasma.
This requires large loading doses to achieve therapeutic plasma levels. Low Vd indicates primarily
plasma binding .
Q6: The half-life (t½) of a drug is:
• A) The time required for 50% of the drug to be eliminated
• B) The time required for the drug to reach peak concentration
• C) The time required for the drug to be completely eliminated
• D) The time required for the drug to reach steady state
Answer: A
Rationale: Half-life determines dosing interval. It takes approximately 4-5 half-lives to reach steady
state and to eliminate the drug .
Q7: Steady state of a drug is typically reached after approximately:
, WGU D116
• A) One half-life
• B) 2-3 half-lives
• C) 4-5 half-lives
• D) 10 half-lives
Answer: C
Rationale: Steady state is reached when the rate of drug administration equals the rate of
elimination, usually after 4-5 half-lives. For a drug with a 24-hour half-life, steady state is reached in
about 5 days .
Q8: The loading dose of a drug is intended to:
• A) Maintain steady state
• B) Achieve therapeutic concentration rapidly
• C) Prolong the half-life
• D) Reduce side effects
Answer: B
Rationale: Loading doses rapidly achieve therapeutic concentrations, especially for drugs with long
half-lives .
Q9: A drug with a narrow therapeutic index requires:
• A) Once-daily dosing regardless of half-life
• B) Careful monitoring of drug levels and clinical response
• C) No monitoring as it is very safe
• D) Administration with food to enhance absorption
Answer: B
Rationale: Narrow therapeutic index drugs have a small margin between effective and toxic doses
(e.g., warfarin, digoxin, lithium, aminoglycosides), requiring therapeutic drug monitoring and close
clinical observation .
Q10: The therapeutic index is best defined as:
• A) The difference between maximum and minimum dose
• B) The ratio of toxic dose (TD50) to effective dose (ED50)
• C) The half-life of a drug
• D) Drug potency
, WGU D116
Answer: B
Rationale: A narrow therapeutic index indicates a small margin of safety and requires therapeutic
drug monitoring .
Q11: Which of the following scenarios best describes a drug acting as a partial agonist?
• A) A drug that binds to a receptor and produces the maximum possible response
• B) A drug that binds to a receptor, produces a submaximal response, and blocks other
agonists from binding
• C) A drug that binds to a receptor and prevents all endogenous and exogenous agonists from
acting
• D) A drug that binds to an allosteric site to enhance the effect of an endogenous agonist
Answer: B
Rationale: Partial agonists bind to the same receptor site as full agonists but produce a submaximal
response even at full receptor occupancy, while simultaneously blocking full agonists from binding .
Q12: A drug that binds to a receptor and produces a maximal biological response is classified as
a(n):
• A) Partial agonist
• B) Competitive antagonist
• C) Full agonist
• D) Inverse agonist
Answer: C
Rationale: Agonists have both high affinity for a receptor and high intrinsic activity, meaning they
fully activate the receptor to elicit a maximal response .
Q13: An antagonist drug:
• A) Activates the receptor
• B) Blocks the receptor (prevents agonist binding)
• C) Has no affinity for the receptor
• D) Is always irreversible
Answer: B
Rationale: An antagonist has high affinity for a receptor but no intrinsic activity. It binds to the
receptor and blocks the action of endogenous ligands or agonists without producing a biological
response .
